Landmark cannabis-based medicine trial targets dementia residents

18 February 2019 – Care Home News

The first cannabis-based medicine licensed in the UK is currently under trial for the treatment of dementia symptoms – recruiting care home residents between 55 and 90 years-old who are displaying symptoms of agitation or aggression.

Savitex is currently licensed in the UK solely for the treatment of Multiple Sclerosis (MS), but Alzheimer’s Research UK called the new trial is significant as there have been “no new dementia treatments in over 15 years”.


%d bloggers like this: